Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The growth of the global hallux valgus treatment market is driven by the rising number of rheumatoid arthritis cases, which was close to 35 million in 2021. Rheumatoid arthritis is among the major factors leading to hallux valgus. The overall market is likely to grow at a CAGR of 5.90% in the forecast period of 2022-2030 and the number of cases is likely to reach close to 38.3 million by 2030.
In May 2021, Zynrelef was approved by the U.S. Food and Drug Administration (FDA) and published by Heron Therapeutics. It is a dual action anaesthetic of bupivacaine-meloxicam with a sustained release mechanism for management of pain. Bupivacaine and low-dose meloxicam are combined in ZYNRELEF to overcome the challenges of inflammatory processes at the surgical site. A diffusion controlled Polychronomer® polymer forms the basis for ZYNRELEF's sustained controlled release of bupivacaine and meloxicam.
A marketing authorization was granted by the European Commission (EC) for ZYNRELEF to treat post-operative somatic pain of mild to moderate surgical wounds in adults in September 2020. Currently, ZYNRELEF is approved in 31 European countries, including the European Union and European economic area.
One of the most common progressive deformities of the forefoot is hallux valgus, also known as bunion. Bunions are "bumpy" growths near the metatarsophalangeal (MTP) joint of the big toe. The development of these bunions and the consequent exacerbation and painful symptoms often occur when a person wears tight and narrow shoes. Apart from narrow shoes, factors like hereditary conditions, rheumatoid arthritis, and polio virus can also cause bunions.
Bunions can be classified clinically into mild, moderate, or severe bunions. Women and the elderly are among the most common patients of the condition, although it can happen to anyone.
Hallux valgus is easy to diagnose, based on the symptoms and the shape of the bump, but to get a better understanding, the doctor may suggest X-ray.
Two angles are widely accepted to study the condition. The intermetatarsal angle is the angle between the first and second metatarsal bones and if the angle is greater than 9 degrees, it is irregular and is called a metatarsus primus varus.
The hallux valgus angle is the angle of the big toe when the big toe is tilted towards the small toe. Angles greater than 15 degrees are considered to be the signs of hallux valgus.
The most important treatment option for bunions is surgery, which is more effective than self-management, pain relievers, and medical devices. A patient's treatment will, however, depend entirely on the severity of their condition.
Although non-surgical treatment would not fix the deformity, it will relieve symptoms to some extent. A physician may suggest surgery if the patient's pain persists despite all these measures.
According to the global hallux valgus treatment market research report, the market can be categorised into the following segments:
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Diagnosis
Market Breakup by Route of Administration
Market Breakup by Treatment Channel
Market Breakup by Region
The increasing prevalence of bone diseases will contribute to growth of the market. In women, hallux valgus is more prevalent than in men, since pointed heels are commonly worn by women. Due to this, the internal and external soft tissues of the foot are ripped or unbalanced, increasing bone disease risk, leading to the growth of the hallux valgus treatment market.
Rapid rise in the prevalence of inflammatory diseases, such as rheumatoid arthritis, increases the risk of hallux valgus deformity, which in turn increases the demand for hallux valgus treatment.
Rising healthcare expenditure also influences the growth of the hallux valgus treatment market. The growth of the market can also be attributed to the increasing efforts by public and private organisations to spread awareness about the deformity and the availability of the treatment and effective therapies.
Factors like changing lifestyles of the population and the rapid rise in the population of working women are contributing to hallux valgus treatment market growth. The growth is also favoured by other factors like rise in consumer disposable income and elderly population.
New opportunities for market growth will also be stimulated by the increased investments and resources for research and development. The market will witness lucrative opportunities during the forecast period as there has been a significant rise in strategic partnerships. to develop cost-effective drugs and therapeutic solutions for hallux valgus treatment.
Strict regulations by FDA for medical device approvals are primarily responsible for impeding the expansion of the hallux valgus treatment market. Apart from strict regulations by the FDA, the market growth is also obstructed in the low-income countries by the high cost of the treatment, and lack of infrastructure.
Lack of awareness of the deformity as well as the lack of availability of treatment in some regions has been a major restraining factor for the growth of the market.
The global market is dominated by North America in terms of market share and revenue and will continue to maintain its dominance during the forecast period as well. The leadership can be attributed to the higher presence of key players in the region, luxury lifestyles of women, and the rising mergers and acquisitions.
Rapid technological advancements are likely to make Europe the second leading region in the hallux valgus treatment market in the coming years.
Rising ageing population and an increase in paediatricians will drive the growth in the Asia Pacific market during the forecast period. In addition, better healthcare infrastructure and growing healthcare spending are expected to boost this region's market growth.
For hallux valgus treatment, these devices are most commonly marketed across the globe:
PROstep Minimally Invasive Surgery System: Wright Medical Technology - PROstep is a minimally invasive surgery (MIS) technology developed by Wright Medical Technology. In order to preserve soft tissue, PROstep MICA and Minimally Invasive Foot and Ankle System are designed with the premise that any "current" procedure can be performed through smaller, less invasive incisions. This system consists of MICA screws, PROstep Burrs, PROstep power boxes, and instruments for minimally invasive procedures, such as Akin, Chevron, Bunionette, and Bunionectomy.
Magnezix CS: Syntellix - Magnezix is a magnesium alloy (MgYREZr) with stable metallic properties, but it is capable of being bioabsorbable and replaced by endogenous tissues in the body. Magnesium is considered an osteoconductive mineral and has an anti-infective effect, according to experimental studies.
Lapiplasty 3-dimensional plastic surgery is an advanced technology developed by Treace Medical Concepts for surgically correcting bunions. In addition to correcting all three dimensions of this bunion deformity problematic root, lapiplasty is the only procedure designed specifically for this problem.
The report gives an in-depth analysis of the key players involved in the hallux valgus treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Treatment||
|Breakup by Diagnosis||
|Breakup by Route of Administration||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Hallux Valgus Treatment Market Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
6 Global Hallux Valgus Treatment Market
6.1 Global Hallux Valgus Treatment Market Overview
6.2 Global Hallux Valgus Treatment Market Analysis
6.2.1 Market Overview
188.8.131.52 Global Hallux Valgus Treatment Historical Market Value (2015-2021)
184.108.40.206 Global Hallux Valgus Treatment Forecast Market Value (2022-2030)
6.3 Global Hallux Valgus Treatment Market by Type
6.3.1 Market Overview
220.127.116.11 Congenital Hallux Valgus
18.104.22.168 Juvenile or Adolescent’s Hallux Valgus
22.214.171.124 Tailer’s Bunion
6.4 Global Hallux Valgus Treatment Market by Treatment
6.4.1 Market Overview
126.96.36.199 Surgical and Mechanical treatment
6.5 Global Hallux Valgus Treatment Market by Diagnosis
6.5.1 Market Overview
188.8.131.52 Medical History
184.108.40.206 Physical Examination
6.6 Global Hallux Valgus Treatment Market by Route of Administration
6.6.1 Market Overview
6.7 Global Hallux Valgus Treatment Market by Treatment Channel
6.8 Global Hallux Valgus Treatment Market by Region
6.8.1 Market Overview
220.127.116.11 North America
18.104.22.168 Asia Pacific
22.214.171.124 Latin America
126.96.36.199 Middle East and Africa
6.8.2 North America
188.8.131.52 Historical Trend (2015-2021)
184.108.40.206 Forecast Trend (2022-2030)
220.127.116.11 Break Up by Country
18.104.22.168.1 United States of America
22.214.171.124 Historical Trend (2015-2021)
126.96.36.199 Forecast Trend (2022-2030)
188.8.131.52 Break Up by Country
184.108.40.206.1 United Kingdom
6.8.4 Asia Pacific
220.127.116.11 Historical Trend (2015-2021)
18.104.22.168 Forecast Trend (2022-2030)
22.214.171.124 Break Up by Country
6.8.5 Latin America
126.96.36.199 Historical Trend (2015-2021)
188.8.131.52 Forecast Trend (2022-2030)
184.108.40.206 Break Up by Country
6.8.6 Middle East and Africa
220.127.116.11 Historical Trend (2015-2021)
18.104.22.168 Forecast Trend (2022-2030)
22.214.171.124 Break Up by Country
126.96.36.199.1 Saudi Arabia
188.8.131.52.2 United Arab Emirates
184.108.40.206.4 South Africa
7 Current Scenario Evaluation
7.1 Emerging Therapies and Clinical trials Synopsis
7.2 Patent Landscape and Impact
7.3 Cost of Treatment
8 Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Hallux Valgus Treatment Industry Dynamics
9.1 Industry Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives & Trends
9.7 Value Chain
10 Supplier Landscape
10.1 Tornier N.V.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.2 Integra Life Sciences Holdings Corporation
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.3 Wright Medical Technology, Inc.
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.4 Smith & Nephew Plc
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.5 Zimmer Biomet Holdings, Inc
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.6 Arthrex, Inc.
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.7 Stryker Corporation
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.9 Biomet Inc
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.10 OrthoHelix Surgical Designs
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.11 Orthofix Holdings Inc
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.13 Mondeal Medical System GmbH
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.14 BioPro Inc
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
11 Recommendations and Discussion
12 Global Hallux Valgus Treatment Distribution Model (Additional Insight)
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
The global market is expected to grow at a CAGR of 5.9% during the forecast period of 2022-2027.
The factors stimulating the development of the market include increased government initiatives, optimal costs, and a rise in R&D expenditure in biopharmaceutical companies.
Fewer drug approvals, stringent government regulations, and lack of awareness are some of the suspected reasons responsible for hindering the growth of the market.
The global market is currently dominated by North America due to the higher presence of key players in the region.
The top companies involved are Tornier N.V., Integra Life Sciences Holdings Corporation, Wright Medical Technology, Inc., Smith & Nephew Plc, Zimmer Biomet Holdings, Inc, Arthrex, Inc., Stryker Corporation, Ossur, Biomet Inc, OrthoHelix Surgical Designs, Orthofix Holdings Inc, Acumen, Mondeal Medical System GmbH, and BioPro Inc.
The most common progressive deformity of the forefoot is hallux valgus, widely known as bunion. Bunions are bumpy growths near the metatarsophalangeal (MTP) joint of the big toe.
Non-surgical treatment of hallux valgus cannot correct the deformity.
Hallux valgus is a genetic disorder and often runs in families. It is commonly seen in patients with excessive pronation who often wear narrow shoes.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.